Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma

Leukemia & Lymphoma
Edward G BrooksDiego Villa

Abstract

The impact of treatment delays on outcomes in Hodgkin lymphoma (HL) is currently unknown. Time from definitive histologic diagnosis to first ABVD treatment (TDT) was calculated in 810 adults with HL: 365 (45%) TDT ≤4 weeks, 369 (46%) TDT 5-8 weeks, 76 (9%) TDT >8 weeks. The 5-year overall survival (OS) was 92% TDT ≤4 weeks, 92% TDT 5-8 weeks, and 83% TDT >8 weeks (p = 0.007). The 5-year disease-specific survival (DSS) was 93% TDT ≤4 weeks, 95% TDT 5-8 weeks, and 87% TDT >8 weeks (p = 0.094). The 5-year progression-free survival (PFS) was similar between groups (p = 0.139). In the multivariate analysis, TDT >8 weeks was not associated with worse OS, DSS, or PFS. Despite the univariate association between initiation of ABVD >8 weeks and worse OS, these data do not support such cut-off to improve outcomes. Nevertheless, clinicians should make every effort possible to initiate curative-intent chemotherapy as soon as a diagnosis of HL is established.

References

Oct 4, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caroline LohrischIvo A Olivotto
Dec 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lucia NogováUNKNOWN German Hodgkin Study Group
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas EngertMarkus Löffler
Sep 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter J HoskinPeter W M Johnson
Dec 17, 2009·The New England Journal of Medicine·George P CanellosJeffrey L Johnson
Jun 7, 2011·JAMA : the Journal of the American Medical Association·James J BiagiChristopher M Booth
Jul 22, 2011·The New England Journal of Medicine·Simonetta VivianiUNKNOWN Intergruppo Italiano Linfomi
Dec 14, 2011·The New England Journal of Medicine·Ralph M MeyerUNKNOWN Eastern Cooperative Oncology Group
Jan 29, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Debora de Melo GagliatoMariana Chavez-Macgregor
Sep 4, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D A EichenauerUNKNOWN ESMO Guidelines Working Group
Oct 18, 2014·British Journal of Haematology·Anna NikonovaMatthew C Cheung

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.